On October 15, 2025 Boehringer Ingelheim and AimedBio, a biotechnology company specializing in the development of antibody-based therapeutics, reported a global collaboration and licensing agreement to develop a novel antibody-drug conjugate (ADC) therapy for a broad range of cancers. The agreement further strengthens Boehringer’s growing ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ADCs are a powerful therapeutic approach that combines biological precision with chemical potency," said Vittoria Zinzalla, Global Head of Experimental Medicine at Boehringer Ingelheim. "Targeting the specific cancer surface marker with AimedBio’s ADC may expand precision medicine treatment options for currently hard to treat cancers and potentially deliver meaningful benefit to patients. We are proud to move this program into the clinic as part of our mission to transform cancer care."
ADCs harness the specificity of monoclonal antibodies and the potency of cytotoxic agents – in this case a derivative of exatecan – to selectively target and eliminate cancer cells while minimizing damage to healthy tissue. The ADC developed by AimedBio targets a protein that is highly expressed across a broad spectrum of cancers, minimally present in normal tissues, and plays a significant role in tumor growth, metastasis and resistance to therapy. Targeting this protein with an ADC is expected to enable highly specific cytotoxic action against the tumor cells, enhancing efficacy and supporting better outcomes for patients.
"We believe this program has the potential to transform the treatment landscape for many cancers that currently lack effective options. Partnering with Boehringer will help advance this program with the speed, scale, and expertise needed to validate this novel target and approach," said Do-Hyun Nam, CTO of AimedBio. "Boehringer’s strong commitment to next-generation cancer therapies makes them the ideal partner to carry this program forward into the clinic and beyond."
Under the terms of the agreement, AimedBio is entitled to receive up to $991 million in total, including an upfront payment, development and regulatory milestones, and commercial milestones, as well as separate royalty payments on net sales.
(Press release, Boehringer Ingelheim, OCT 15, 2025, View Source [SID1234656704])